
Quarterly report 2025-Q3
added 11-04-2025
Repligen Corporation Net Debt 2011-2026 | RGEN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Repligen Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -236 M | -385 M | -493 M | - | -265 M | -90.3 M | -74.5 M | -7.41 M | -54.1 M | -35.4 M | -39.8 M | -29.2 M | -14.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.41 M | -493 M | -144 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
11.5 B | $ 19.11 | -1.04 % | $ 9.75 B | ||
|
Becton, Dickinson and Company
BDX
|
17.1 B | $ 194.62 | -0.57 % | $ 56 B | ||
|
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
-5.61 M | $ 8.8 | -16.82 % | $ 177 M | ||
|
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
2.46 B | $ 78.92 | -0.49 % | $ 40.4 B | ||
|
Harvard Bioscience
HBIO
|
27.8 M | $ 0.67 | 1.38 % | $ 28.4 M | ||
|
AtriCure
ATRC
|
-59.2 M | $ 39.59 | -1.47 % | $ 1.86 B | ||
|
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M | ||
|
ICU Medical
ICUI
|
1.24 B | $ 142.71 | -1.33 % | $ 3.48 B | ||
|
electroCore
ECOR
|
-9.7 M | $ 4.51 | -3.12 % | $ 24.9 K | ||
|
iRhythm Technologies
IRTC
|
-329 M | $ 177.87 | -0.39 % | $ 5.55 B | ||
|
AngioDynamics
ANGO
|
-48.3 M | $ 12.82 | -1.38 % | $ 524 M | ||
|
Isoray
ISR
|
-58.9 M | - | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
2.38 B | $ 82.0 | -0.57 % | $ 16.3 B | ||
|
Repro Med Systems
KRMD
|
-10.8 M | $ 5.82 | 2.28 % | $ 265 M | ||
|
Glaukos Corporation
GKOS
|
-21.6 M | $ 112.87 | -1.1 % | $ 5.47 B | ||
|
LeMaitre Vascular
LMAT
|
145 M | $ 81.43 | -1.9 % | $ 1.83 B | ||
|
Haemonetics Corporation
HAE
|
623 M | $ 80.27 | -1.06 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
33.3 M | $ 8.86 | -0.56 % | $ 183 M | ||
|
Masimo Corporation
MASI
|
572 M | $ 130.07 | -0.76 % | $ 6.93 B | ||
|
Merit Medical Systems
MMSI
|
363 M | $ 88.04 | -0.59 % | $ 5.13 B | ||
|
Intuitive Surgical
ISRG
|
-1.88 B | $ 567.99 | -0.81 % | $ 202 B | ||
|
Microbot Medical
MBOT
|
-2.24 M | $ 1.97 | -4.15 % | $ 20.1 M | ||
|
Milestone Scientific
MLSS
|
-3.09 M | $ 0.27 | -0.22 % | $ 21.5 M | ||
|
Nephros
NEPH
|
-2.48 M | $ 4.91 | 4.13 % | $ 51 M | ||
|
OraSure Technologies
OSUR
|
-266 M | $ 2.39 | -3.24 % | $ 178 M | ||
|
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
244 M | $ 21.77 | -0.68 % | $ 3.75 B | ||
|
Pro-Dex
PDEX
|
15 M | $ 38.38 | -0.56 % | $ 126 M | ||
|
Predictive Oncology
POAI
|
1.4 M | - | - | $ 32.4 M | ||
|
Pulse Biosciences
PLSE
|
-35.2 M | $ 13.66 | -0.29 % | $ 656 M | ||
|
ResMed
RMD
|
513 M | $ 241.11 | -0.82 % | $ 35.2 B | ||
|
BioLife Solutions
BLFS
|
-88.9 M | $ 24.25 | -1.66 % | $ 1.12 B | ||
|
STERIS plc
STE
|
1.78 B | $ 254.18 | -0.5 % | $ 25.1 B | ||
|
Stereotaxis
STXS
|
-14.3 M | $ 2.28 | -0.66 % | $ 184 M | ||
|
Retractable Technologies
RVP
|
-3 M | $ 0.76 | -3.28 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
-105 M | $ 23.07 | -0.62 % | $ 1.13 B | ||
|
Teleflex Incorporated
TFX
|
1.37 B | $ 121.85 | 0.18 % | $ 5.71 B | ||
|
Utah Medical Products
UTMD
|
-60.6 M | $ 56.1 | -0.32 % | $ 204 M | ||
|
DENTSPLY SIRONA
XRAY
|
1.36 B | $ 11.41 | 0.13 % | $ 2.32 B | ||
|
West Pharmaceutical Services
WST
|
-264 M | $ 275.08 | -0.65 % | $ 20.1 B |